© 2017 Pharmstandard Ventures
ArTara Therapeutic
(NASDAQ: TARA)
New York, NY, USA
Year of Investment: 2014
IPO in October, 2014
Merger transaction between Proteon and ArTara in January, 2020
ArTara Therapeutic
(NASDAQ: TARA)
New York, NY, USA
Year of Investment: 2014
IPO in October, 2014
Merger transaction between Proteon and ArTara in January, 2020
ArTara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. ArTara's current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company's lead program, TARA-002, is being developed for the treatment of lymphatic malformations. ArTara's second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of IFALD.
For more information, please visit:

https://artaratx.com

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally